<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on September 20, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/ct2/show/NCT04408261</url>
  </required_header>
  <id_info>
    <org_study_id>2017L04609</org_study_id>
    <nct_id>NCT04408261</nct_id>
  </id_info>
  <brief_title>BuqitongluO Granule for Qi Deficiency and Blood Stasis Syndrome</brief_title>
  <acronym>BOSS</acronym>
  <official_title>Buqitongluo Granule for Qi Deficiency and Blood Stasis Syndrome: A Multicenter, Randomized, Double-blind, Placebo-Controlled Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Dongzhimen Hospital, Beijing</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>The Affiliated Hospital of Changchun University of Chinese Medicine</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>The Affiliated Hospital of Shandong University of Chinese Medicine</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>The Affiliated Hospital of Chengdu University of Chinese Medicine</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>The Second Affiliated Hospital of Tianjin University of Traditional Chinese Medicine</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>The First Affiliated Hospital of Heilongjiang University of Traditional Chinese Medicine</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>The Second Affiliated Hospital of Heilongjiang University of Traditional Chinese Medicine</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>The Second Affiliated Hospital of Hunan University of Traditional Chinese Medicine</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Hunan Academy of Traditional Chinese Medicine Affiliated Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>The First Clinical Hospital of Jilin Academy of Traditional Chinese Medicine</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Shaanxi Buchang Pharmaceuticals Co., Ltd.</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Beijing Chuanglikechuang Medical Technology Development Co., Ltd.</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Shanghai Youningwei Biotechnology Co., Ltd.</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Wuhan Zhizhi Medical Technology Co., Ltd.</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Wuhan Third Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Rizhao Hospital of Traditional Chinese Medicine</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>The First Affiliated Hospital of Guangxi University of Traditional Chinese Medicine</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Jiangbin Hospital of Guangxi Zhuang Autonomous Region</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Dongzhimen Hospital, Beijing</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The main purpose of this trial is to evaluate the efficacy and safety of Buqitongluo Granule&#xD;
      in treating qi deficiency and blood stasis syndrome, and explore the effect of the&#xD;
      improvement of qi deficiency and blood stasis syndrome on the prognosis of diseases.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The BOSS study is a multicenter, randomized, double-blind, placebo-controlled clinical trial.&#xD;
      The primary hypothesis of this trial is that Buqitongluo Granule will improve the syndrome&#xD;
      score of Qi Deficiency and Blood Stasis in convalescence of ischemic stroke, stable angina&#xD;
      pectoris of coronary artery disease and diabetic peripheral neuropathy with qi deficiency and&#xD;
      blood stasis syndrome. Buqitongluo Granule will be compared to placebo, combined with&#xD;
      guidelines-based standard care in patients. During the trial, it is forbidden to use&#xD;
      acupuncture, Traditional Chinese Medicine decoction (compound granule), Traditional Chinese&#xD;
      Medicine injection, Chinese patent medicine (including external use), external washing of&#xD;
      Traditional Chinese Medicine and health product (composition or efficacy similar to the study&#xD;
      drug).&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date type="Actual">July 22, 2020</start_date>
  <completion_date type="Anticipated">December 2022</completion_date>
  <primary_completion_date type="Anticipated">December 2022</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in the syndrome score of Qi Deficiency and Blood Stasis</measure>
    <time_frame>Baseline, at day 14, day 28, day 42 during treatment, and at day 14 after treatment</time_frame>
    <description>The dynamic evaluation will be defined by Evaluation Scale of Qi Deficiency and Blood Stasis Syndrome. The Evaluation Scale of Qi Deficiency and Blood Stasis Syndrome score ranges from 0 (best score) to 51 (worst score).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Neurological impairment will be evaluated by National Institute of Health Stroke Scale (NIHSS) for convalescence of ischemic stroke</measure>
    <time_frame>Baseline, at day 14, day 28, day 42 during treatment</time_frame>
    <description>The NIHSS score ranges from 0 (best score) to 42 (worst score).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Self-rating symptoms will be evaluated by Visual Analog Scale (VAS) for convalescence of ischemic stroke</measure>
    <time_frame>Baseline, at day 14, day 28, day 42 during treatment, and at day 14 after treatment</time_frame>
    <description>Including limb numbness, swelling of hands or feet, spontaneous sweating (hemilateral sweating). Participants rated their symptoms on the 100 millimeter (mm) Visual Analog Scale (VAS) ranging from 0 mm (no symptom) to 100 mm (worst symptom).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Continuous changes of Modified Rankin Scale for convalescence of ischemic stroke</measure>
    <time_frame>Baseline, at day 42 during treatment, and at 90 days after onset</time_frame>
    <description>The Modified Rankin Scale score ranges from 0 (best score) to 6 (worst score).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Activities of daily living will be measured by Barthel Index (BI) score for convalescence of ischemic stroke</measure>
    <time_frame>Baseline, at day 42 during treatment, and at 90 days after onset</time_frame>
    <description>The Barthel Index score ranges from 0 (worst score) to 100 (best score).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life will be measured by Short Form 36 (SF-36) Quality of Life Scale for convalescence of ischemic stroke</measure>
    <time_frame>Baseline, at day 42 during treatment, and at 90 days after onset</time_frame>
    <description>The SF-36 quality of life scale is used to monitor change in subject reported functionality, well-being, and overall health status. The score of each part ranges from 0 (worst score) to 100 (best score).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change of the Seattle Angina Questionnaire (SAQ) Score for stable angina pectoris of coronary artery disease</measure>
    <time_frame>Baseline, at day 28 during treatment, at day 14 after treatment, and at 90 days after recruitment</time_frame>
    <description>The maximum score is 100, and the higher the score, the better the quality of life and the state of body function of patient.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Self-rating symptoms will be evaluated by Visual Analog Scale (VAS) for stable angina pectoris of coronary artery disease</measure>
    <time_frame>Baseline, at day 14, day 28, day 42 during treatment, and at day 14 after treatment</time_frame>
    <description>Including chest tightness, chest pain, palpitation, fatigue, spontaneous sweating. Participants rated their symptoms on the 100 millimeter (mm) Visual Analog Scale (VAS) ranging from 0 mm (no symptom) to 100 mm (worst symptom).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change of the Clinical Scoring System of Toronto (TCSS) for diabetic peripheral neuropathy</measure>
    <time_frame>Baseline, at day 14, day 28, day 42 during treatment, at day 14 after treatment, and at 90 days after recruitment</time_frame>
    <description>TCSS includes a score of neural symptoms, nerve reflex scores and sensory examination. The TCSS score ranges from 0 (best score) to 19 (worst score).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Self-rating symptoms will be evaluated by Visual Analog Scale (VAS) for diabetic peripheral neuropathy</measure>
    <time_frame>Baseline, at day 14, day 28, day 42 during treatment, and at day 14 after treatment</time_frame>
    <description>Including local pain, limb numbness, paresthesia (e.g. burning sensation, formication, electrical sensation). Participants rated their symptoms on the 100 millimeter (mm) Visual Analog Scale (VAS) ranging from 0 mm (no symptom) to 100 mm (worst symptom).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life will be measured by Short Form 36 (SF-36) Quality of Life Scale for stable angina pectoris of coronary artery disease and diabetic peripheral neuropathy</measure>
    <time_frame>Baseline, at day 42 during treatment, and at 90 days after recruitment</time_frame>
    <description>The SF-36 quality of life scale is used to monitor change in subject reported functionality, well-being, and overall health status. The score of each part ranges from 0 (worst score) to 100 (best score).</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">432</enrollment>
  <condition>Stroke, Ischemic</condition>
  <condition>Coronary Artery Disease</condition>
  <condition>Angina Pectoris, Stable</condition>
  <condition>Diabetic Peripheral Neuropathy</condition>
  <arm_group>
    <arm_group_label>Buqitongluo Granule</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects will receive orally administered Buqitongluo Granules, combined with guidelines-based standard care.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Subjects will receive orally administered Buqitongluo Granule placeboes, combined with guidelines-based standard care.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Buqitongluo Granule</intervention_name>
    <description>Buqitongluo Granules were dissolved with boiled water, administered orally, each bag of 10 grams, one bag each time, three times a day for 42 days.</description>
    <arm_group_label>Buqitongluo Granule</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Buqitongluo Granule Placebo</intervention_name>
    <description>Buqitongluo Granule placeboes were dissolved with boiled water, administered orally, each bag of 10 grams, one bag each time, three times a day for 42 days.</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Standard care</intervention_name>
    <description>Guidelines-based standard care for convalescence of ischemic stroke, stable angina pectoris of coronary artery disease or diabetic peripheral neuropathy.</description>
    <arm_group_label>Buqitongluo Granule</arm_group_label>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Convalescence of ischemic stroke&#xD;
&#xD;
        Inclusion Criteria:&#xD;
&#xD;
          -  Diagnosis of qi deficiency and blood stasis syndrome&#xD;
&#xD;
          -  Diagnosis of ischemic stroke&#xD;
&#xD;
          -  Age ≥ 35 and ≤ 80 years&#xD;
&#xD;
          -  The interval from the onset to recruitment was 14-30 days&#xD;
&#xD;
          -  NIHSS score ≥ 4 and ≤ 22&#xD;
&#xD;
          -  Patient or legally authorized representative has signed informed consent.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Confirmed secondary stroke caused by tumor, brain trauma, or hematological diseases by&#xD;
             clinical examination;&#xD;
&#xD;
          -  Other conditions that lead to motor dysfunction (e.g. lameness, osteoarthrosis,&#xD;
             rheumatoid arthritis, gouty arthritis), which render the neurological function&#xD;
             examination unlikely to be assessed;&#xD;
&#xD;
          -  Uncontrolled hypertension (systolic blood pressure ≥ 160 mmHg or diastolic blood&#xD;
             pressure ≥ 100 mmHg), or renal or hepatic insufficiency (hepatic insufficiency is&#xD;
             defined as an alanine aminotransferase (ALT) or aspartate aminotransferase (AST) value&#xD;
             that is 1.5 times the upper limit of normal, renal insufficiency is defined as a serum&#xD;
             creatinine concentration value that is over the upper limit of normal);&#xD;
&#xD;
          -  Other conditions or mental disorders which according to the judgement of researchers&#xD;
             that restrict evaluation of mental function or render outcomes or follow-up unlikely&#xD;
             to be assessed;&#xD;
&#xD;
          -  Woman with pregnancy, lactation, or woman who wants to be pregnant in recent;&#xD;
&#xD;
          -  Patient who is allergic to the study drug or has severe allergic constitution;&#xD;
&#xD;
          -  Patient with yellow thick slimy tongue coating;&#xD;
&#xD;
          -  Patient who has been participated in other drug or device clinical trials in recent 3&#xD;
             months.&#xD;
&#xD;
        Stable angina pectoris of coronary artery disease&#xD;
&#xD;
        Inclusion Criteria:&#xD;
&#xD;
          -  Diagnosis of qi deficiency and blood stasis syndrome&#xD;
&#xD;
          -  Diagnosis of stable angina pectoris of coronary artery disease&#xD;
&#xD;
          -  Age ≥ 35 and ≤ 80 years&#xD;
&#xD;
          -  Canadian Cardiovascular Society (CCS) Classification of Angina Pectoris classⅠ-Ⅲ&#xD;
&#xD;
          -  Patient or legally authorized representative has signed informed consent.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Acute coronary syndrome or unstable angina pectoris in the prior 3 months, or other&#xD;
             heart diseases (e.g. cardiomyopathy, pericardial disease);&#xD;
&#xD;
          -  Severe cardiopulmonary insufficiency (congestive heart failure NYHA class IV, severe&#xD;
             abnormal pulmonary function), or severe arrhythmias (e.g. rapid atrial fibrillation,&#xD;
             atrial flutter, paroxysmal ventricular tachycardia);&#xD;
&#xD;
          -  Uncontrolled hypertension (systolic blood pressure ≥ 160 mmHg or diastolic blood&#xD;
             pressure ≥ 100 mmHg), or renal or hepatic insufficiency (hepatic insufficiency is&#xD;
             defined as an alanine aminotransferase (ALT) or aspartate aminotransferase (AST) value&#xD;
             that is 1.5 times the upper limit of normal, renal insufficiency is defined as a serum&#xD;
             creatinine concentration value that is over the upper limit of normal);&#xD;
&#xD;
          -  Other conditions or mental disorders which according to the judgement of researchers&#xD;
             that restrict evaluation of mental function or render outcomes or follow-up unlikely&#xD;
             to be assessed;&#xD;
&#xD;
          -  Woman with pregnancy, lactation, or woman who wants to be pregnant in recent;&#xD;
&#xD;
          -  Patient who is allergic to the study drug or has severe allergic constitution;&#xD;
&#xD;
          -  Patient with yellow thick slimy tongue coating;&#xD;
&#xD;
          -  Patient who has been participated in other drug or device clinical trials in recent 3&#xD;
             months.&#xD;
&#xD;
        Diabetic peripheral neuropathy&#xD;
&#xD;
        Inclusion Criteria:&#xD;
&#xD;
          -  Diagnosis of qi deficiency and blood stasis syndrome&#xD;
&#xD;
          -  Diagnosis of diabetic peripheral neuropathies&#xD;
&#xD;
          -  Age ≥ 35 and ≤ 80 years&#xD;
&#xD;
          -  Patient or legally authorized representative has signed informed consent.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  HbA1c &gt;10% in the screening period;&#xD;
&#xD;
          -  Acute critical disease of diabetes mellitus in the prior 3 months (e.g. hyperglycemia&#xD;
             and hypertonic syndrome, diabetic lactic acidosis, diabetic ketoacidosis);&#xD;
&#xD;
          -  Severe heart disease, brain disease, or kidney disease;&#xD;
&#xD;
          -  Uncontrolled hypertension (systolic blood pressure ≥ 160 mmHg or diastolic blood&#xD;
             pressure ≥ 100 mmHg), or renal or hepatic insufficiency (hepatic insufficiency is&#xD;
             defined as an alanine aminotransferase (ALT) or aspartate aminotransferase (AST) value&#xD;
             that is 1.5 times the upper limit of normal, renal insufficiency is defined as a serum&#xD;
             creatinine concentration value that is over the upper limit of normal);&#xD;
&#xD;
          -  Patient with spinal cord injury, cervical or lumbar vertebra disease (nerve root&#xD;
             compression, spinal stenosis, cervical or lumbar vertebra degenerative disease), or&#xD;
             sequelae of cerebrovascular disease, neuromuscular junction or muscular disease;&#xD;
&#xD;
          -  Neuropathies caused by other diseases (e.g. Guillain-Barre syndrome, chronic&#xD;
             inflammatory demyelinating polyneuropathy (CIDP), VitB deficiency, hypothyroidism,&#xD;
             alcoholism, severe arteriovenous vasculopathy such as venous embolism, lymphangitis);&#xD;
&#xD;
          -  Other conditions or mental disorders which according to the judgement of researchers&#xD;
             that restrict evaluation of mental function or render outcomes or follow-up unlikely&#xD;
             to be assessed;&#xD;
&#xD;
          -  Woman with pregnancy, lactation, or woman who wants to be pregnant in recent;&#xD;
&#xD;
          -  Patient who is allergic to the study drug or has severe allergic constitution;&#xD;
&#xD;
          -  Patient with yellow thick slimy tongue coating;&#xD;
&#xD;
          -  Patient with red tongue and scanty tongue coating;&#xD;
&#xD;
          -  Patient who has been participated in other drug or device clinical trials in recent 3&#xD;
             months.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>35 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ying Gao, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Dongzhimen Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Ying Gao, MD</last_name>
    <phone>0086-010-84013209</phone>
    <email>gaoying973@126.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Weidi Liu</last_name>
    <phone>0086-15301025939</phone>
    <email>L305613099@163.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Dongzhimen Hospital</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>100700</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ying Gao, MD</last_name>
      <phone>0086-010-84013209</phone>
      <email>gaoying973@126.com</email>
    </contact>
    <contact_backup>
      <last_name>Weidi Liu</last_name>
      <phone>0086-15301025939</phone>
      <email>L305613099@163.com</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>May 2020</verification_date>
  <study_first_submitted>May 26, 2020</study_first_submitted>
  <study_first_submitted_qc>May 26, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">May 29, 2020</study_first_posted>
  <last_update_submitted>March 29, 2021</last_update_submitted>
  <last_update_submitted_qc>March 29, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">April 1, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Dongzhimen Hospital, Beijing</investigator_affiliation>
    <investigator_full_name>Ying Gao</investigator_full_name>
    <investigator_title>President of the Institute for Brain Disorders, Beijing University of Chinese Medicine</investigator_title>
  </responsible_party>
  <keyword>Qi Deficiency and Blood Stasis Syndrome</keyword>
  <keyword>Buqitongluo Granule</keyword>
  <keyword>Traditional Chinese Medicine</keyword>
  <keyword>Double-Blind</keyword>
  <keyword>Randomized Controlled Trial</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Blind Loop Syndrome</mesh_term>
    <mesh_term>Peripheral Nervous System Diseases</mesh_term>
    <mesh_term>Ischemic Stroke</mesh_term>
    <mesh_term>Coronary Artery Disease</mesh_term>
    <mesh_term>Angina Pectoris</mesh_term>
    <mesh_term>Angina, Stable</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>


download date: ClinicalTrials.gov processed this data on September 20, 2023
link text: Link to the current ClinicalTrials.gov record.
url: https://clinicaltrials.gov/ct2/show/NCT04408261
org study id: 2017L04609
nct id: NCT04408261
lead sponsor: 
collaborator: 
collaborator: 
collaborator: 
collaborator: 
collaborator: 
collaborator: 
collaborator: 
collaborator: 
collaborator: 
collaborator: 
collaborator: 
collaborator: 
collaborator: 
collaborator: 
collaborator: 
collaborator: 
collaborator: 
has dmc: Yes
is fda regulated drug: No
is fda regulated device: No
The main purpose of this trial is to evaluate the efficacy and safety of Buqitongluo Granule
      in treating qi deficiency and blood stasis syndrome, and explore the effect of the
      improvement of qi deficiency and blood stasis syndrome on the prognosis of diseases.
The BOSS study is a multicenter, randomized, double-blind, placebo-controlled clinical trial.
      The primary hypothesis of this trial is that Buqitongluo Granule will improve the syndrome
      score of Qi Deficiency and Blood Stasis in convalescence of ischemic stroke, stable angina
      pectoris of coronary artery disease and diabetic peripheral neuropathy with qi deficiency and
      blood stasis syndrome. Buqitongluo Granule will be compared to placebo, combined with
      guidelines-based standard care in patients. During the trial, it is forbidden to use
      acupuncture, Traditional Chinese Medicine decoction (compound granule), Traditional Chinese
      Medicine injection, Chinese patent medicine (including external use), external washing of
      Traditional Chinese Medicine and health product (composition or efficacy similar to the study
      drug).
allocation: Randomized
intervention model: Parallel Assignment
primary purpose: Treatment
masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
measure: Change in the syndrome score of Qi Deficiency and Blood Stasis
time frame: Baseline, at day 14, day 28, day 42 during treatment, and at day 14 after treatment
description: The dynamic evaluation will be defined by Evaluation Scale of Qi Deficiency and Blood Stasis Syndrome. The Evaluation Scale of Qi Deficiency and Blood Stasis Syndrome score ranges from 0 (best score) to 51 (worst score).
measure: Neurological impairment will be evaluated by National Institute of Health Stroke Scale (NIHSS) for convalescence of ischemic stroke
time frame: Baseline, at day 14, day 28, day 42 during treatment
description: The NIHSS score ranges from 0 (best score) to 42 (worst score).
measure: Self-rating symptoms will be evaluated by Visual Analog Scale (VAS) for convalescence of ischemic stroke
time frame: Baseline, at day 14, day 28, day 42 during treatment, and at day 14 after treatment
description: Including limb numbness, swelling of hands or feet, spontaneous sweating (hemilateral sweating). Participants rated their symptoms on the 100 millimeter (mm) Visual Analog Scale (VAS) ranging from 0 mm (no symptom) to 100 mm (worst symptom).
measure: Continuous changes of Modified Rankin Scale for convalescence of ischemic stroke
time frame: Baseline, at day 42 during treatment, and at 90 days after onset
description: The Modified Rankin Scale score ranges from 0 (best score) to 6 (worst score).
measure: Activities of daily living will be measured by Barthel Index (BI) score for convalescence of ischemic stroke
time frame: Baseline, at day 42 during treatment, and at 90 days after onset
description: The Barthel Index score ranges from 0 (worst score) to 100 (best score).
measure: Quality of life will be measured by Short Form 36 (SF-36) Quality of Life Scale for convalescence of ischemic stroke
time frame: Baseline, at day 42 during treatment, and at 90 days after onset
description: The SF-36 quality of life scale is used to monitor change in subject reported functionality, well-being, and overall health status. The score of each part ranges from 0 (worst score) to 100 (best score).
measure: Change of the Seattle Angina Questionnaire (SAQ) Score for stable angina pectoris of coronary artery disease
time frame: Baseline, at day 28 during treatment, at day 14 after treatment, and at 90 days after recruitment
description: The maximum score is 100, and the higher the score, the better the quality of life and the state of body function of patient.
measure: Self-rating symptoms will be evaluated by Visual Analog Scale (VAS) for stable angina pectoris of coronary artery disease
time frame: Baseline, at day 14, day 28, day 42 during treatment, and at day 14 after treatment
description: Including chest tightness, chest pain, palpitation, fatigue, spontaneous sweating. Participants rated their symptoms on the 100 millimeter (mm) Visual Analog Scale (VAS) ranging from 0 mm (no symptom) to 100 mm (worst symptom).
measure: Change of the Clinical Scoring System of Toronto (TCSS) for diabetic peripheral neuropathy
time frame: Baseline, at day 14, day 28, day 42 during treatment, at day 14 after treatment, and at 90 days after recruitment
description: TCSS includes a score of neural symptoms, nerve reflex scores and sensory examination. The TCSS score ranges from 0 (best score) to 19 (worst score).
measure: Self-rating symptoms will be evaluated by Visual Analog Scale (VAS) for diabetic peripheral neuropathy
time frame: Baseline, at day 14, day 28, day 42 during treatment, and at day 14 after treatment
description: Including local pain, limb numbness, paresthesia (e.g. burning sensation, formication, electrical sensation). Participants rated their symptoms on the 100 millimeter (mm) Visual Analog Scale (VAS) ranging from 0 mm (no symptom) to 100 mm (worst symptom).
measure: Quality of life will be measured by Short Form 36 (SF-36) Quality of Life Scale for stable angina pectoris of coronary artery disease and diabetic peripheral neuropathy
time frame: Baseline, at day 42 during treatment, and at 90 days after recruitment
description: The SF-36 quality of life scale is used to monitor change in subject reported functionality, well-being, and overall health status. The score of each part ranges from 0 (worst score) to 100 (best score).
arm group label: Buqitongluo Granule
arm group type: Experimental
description: Subjects will receive orally administered Buqitongluo Granules, combined with guidelines-based standard care.
arm group label: Placebo
arm group type: Placebo Comparator
description: Subjects will receive orally administered Buqitongluo Granule placeboes, combined with guidelines-based standard care.
intervention type: Drug
intervention name: Buqitongluo Granule
description: Buqitongluo Granules were dissolved with boiled water, administered orally, each bag of 10 grams, one bag each time, three times a day for 42 days.
arm group label: Buqitongluo Granule
intervention type: Drug
intervention name: Buqitongluo Granule Placebo
description: Buqitongluo Granule placeboes were dissolved with boiled water, administered orally, each bag of 10 grams, one bag each time, three times a day for 42 days.
arm group label: Placebo
intervention type: Other
intervention name: Standard care
description: Guidelines-based standard care for convalescence of ischemic stroke, stable angina pectoris of coronary artery disease or diabetic peripheral neuropathy.
arm group label: Buqitongluo Granule
arm group label: Placebo
criteria: 
gender: All
minimum age: 35 Years
maximum age: 80 Years
healthy volunteers: No
last name: Ying Gao, MD
role: Principal Investigator
affiliation: Dongzhimen Hospital
last name: Ying Gao, MD
phone: 0086-010-84013209
email: gaoying973@126.com
last name: Weidi Liu
phone: 0086-15301025939
email: L305613099@163.com
facility: 
status: Recruiting
contact: 
contact backup: 
country: China
responsible party type: Principal Investigator
investigator affiliation: Dongzhimen Hospital, Beijing
investigator full name: Ying Gao
investigator title: President of the Institute for Brain Disorders, Beijing University of Chinese Medicine
mesh term: Blind Loop Syndrome
mesh term: Peripheral Nervous System Diseases
mesh term: Ischemic Stroke
mesh term: Coronary Artery Disease
mesh term: Angina Pectoris
mesh term: Angina, Stable